

**PRESS RELEASE**

Noida, **Dec 1, 2025**

**Jubilant Pharmova Limited**

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

## **Appointment of Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc., step down subsidiary of Jubilant Pharmova Limited**

Jubilant Pharmova Limited announces the appointment of Daniel J. O'Connor as the CEO of its Proprietary Novel drugs business.

Dan brings more than 30 years of leadership experience in Biotechnology and Oncology, with a proven record of creating value around differentiated, IP-rich platforms. Most recently, he served as CEO of Ambrx Biopharma, where his leadership drove a significant increase in company valuation culminating in its successful acquisition.

Earlier in his career, Dan was instrumental at ImClone Systems, contributing to the clinical development, launch, and commercialization of a major oncology therapy while navigating complex intellectual property and inventorship challenges. He also served as CEO of Advaxis, a NASDAQ-listed immuno-oncology company, where he transformed the organization into a late-stage clinical enterprise, secured substantial growth capital, and forged strategic collaborations with leading pharmaceutical partners.

Commenting on the occasion, **Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharmova Limited**, said, “We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications.”

On the Occasion, **Mr. Daniel J. O'Connor**, said, “I am honoured to lead Jubilant Therapeutics, a company dedicated to driving breakthrough innovation for cancers that are difficult to treat. I look forward to collaborating closely with our talented team to advance our mission and deliver meaningful value to patients, partners, and stakeholders alike.”

### **About Jubilant Therapeutics Inc.**

Jubilant Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients. Its advanced structure-based discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships. The Company's clinical pipeline consists of a first in class dual CoREST modifier, JBI-802, currently in a Phase I/II clinical trial in multiple tumors and a novel brain-penetrant modulator of PRMT5, currently in Phase I clinical trial. Additional pre-clinical programs include brain penetrant and gut restrictive PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications. The Company is headquartered in Pennsylvania and guided by globally renowned scientific advisors.

For more information, please visit [www.jubilanttx.com](http://www.jubilanttx.com) or follow us on X @JubilantTx and [LinkedIn](#).

## About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 45 radiopharmacies in the US. The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant Pharmova Limited through its CDMO Sterile Injectables business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world-class research centers in Bengaluru and Noida in India and one in France. The CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and autoimmune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a 'Partner of Choice' by leading pharmaceuticals companies globally.

### For more information, please contact:

#### For Investors

##### **Pankaj Dhawan**

Phone: +91 120 436 1105

E-mail: [Pankaj.dhawan@jUBL.com](mailto:Pankaj.dhawan@jUBL.com)

#### **Siddharth Rangnekar**

CDR India

Phone: +91 97699 19966

E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

#### For Media

##### **Sandipan Ghatak**

Phone: +91 98107 76182

E-mail: [sandipan.ghatak@jUBL.com](mailto:sandipan.ghatak@jUBL.com)

#### **Jyoti Sharma**

Ad Factors PR

Phone: +91 9810519900

E-mail: [jyoti.sharma@adfacitorspr.com](mailto:jyoti.sharma@adfacitorspr.com)

## Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.